← Back to Screener
Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)
Price$87.72
Favorite Metrics
Price vs S&P 500 (26W)-20.78%
Price vs S&P 500 (4W)-8.08%
Market Capitalization$5.99B
All Metrics
Book Value / Share (Quarterly)$4.02
P/TBV (Annual)26.99x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)100.22%
Cash Flow / Share (Quarterly)$-1.74
Price vs S&P 500 (YTD)-21.28%
Gross Margin (TTM)89.73%
Net Profit Margin (TTM)-103.57%
EPS (TTM)$-3.03
10-Day Avg Trading Volume0.62M
EPS Excl Extra (TTM)$-3.03
EPS (Annual)$-3.02
ROI (Annual)-51.97%
Gross Margin (Annual)89.73%
Net Profit Margin (5Y Avg)-703.67%
Cash / Share (Quarterly)$5.79
Revenue Growth QoQ (YoY)36.87%
ROA (Last FY)-40.93%
Revenue Growth TTM (YoY)45.83%
EBITD / Share (TTM)$-2.92
ROE (5Y Avg)-86.59%
Operating Margin (TTM)-101.19%
Cash Flow / Share (Annual)$-1.74
P/B Ratio22.18x
P/B Ratio (Quarterly)26.45x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)31.85x
Net Interest Coverage (TTM)-36.06x
ROA (TTM)-45.01%
EPS Incl Extra (Annual)$-3.02
Current Ratio (Annual)4.41x
Quick Ratio (Quarterly)3.92x
3-Month Avg Trading Volume0.84M
52-Week Price Return44.59%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.94
P/S Ratio (Annual)31.57x
Asset Turnover (Annual)0.40x
52-Week High$122.20
Operating Margin (5Y Avg)-1339.99%
EPS Excl Extra (Annual)$-3.02
CapEx CAGR (5Y)35.32%
Tangible BV CAGR (5Y)12.11%
26-Week Price Return-12.03%
Quick Ratio (Annual)4.01x
13-Week Price Return-21.75%
Total Debt / Equity (Annual)0.40x
Current Ratio (Quarterly)4.41x
Enterprise Value$6,043.845
Asset Turnover (TTM)0.43x
Book Value / Share Growth (5Y)1.29%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.88x
Pretax Margin (Annual)-103.31%
Cash / Share (Annual)$5.79
3-Month Return Std Dev53.19%
Gross Margin (5Y Avg)87.94%
Net Income / Employee (TTM)$-0
ROE (Last FY)-72.79%
Net Interest Coverage (Annual)-36.07x
EPS Basic Excl Extra (Annual)$-3.02
Receivables Turnover (TTM)8.51x
Total Debt / Equity (Quarterly)0.40x
EPS Incl Extra (TTM)$-3.03
Receivables Turnover (Annual)8.51x
ROI (TTM)-60.53%
P/S Ratio (TTM)31.57x
Pretax Margin (5Y Avg)-703.42%
Revenue / Share (Annual)$2.92
Tangible BV / Share (Annual)$3.94
Price vs S&P 500 (52W)9.49%
Year-to-Date Return-17.14%
5-Day Price Return2.17%
EPS Normalized (Annual)$-3.02
ROA (5Y Avg)-46.27%
Net Profit Margin (Annual)-103.57%
Month-to-Date Return1.98%
Cash Flow / Share (TTM)$-3.23
EBITD / Share (Annual)$-2.91
Operating Margin (Annual)-101.19%
LT Debt / Equity (Annual)0.37x
ROI (5Y Avg)-58.33%
LT Debt / Equity (Quarterly)0.37x
EPS Basic Excl Extra (TTM)$-3.03
P/TBV (Quarterly)26.99x
P/B Ratio (Annual)26.45x
Inventory Turnover (TTM)0.88x
Pretax Margin (TTM)-103.31%
Book Value / Share (Annual)$4.02
Price vs S&P 500 (13W)-24.61%
Beta2.05x
Revenue / Share (TTM)$2.84
ROE (TTM)-91.16%
52-Week Low$55.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.27
4.27
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RYTMRhythm Pharmaceuticals, Inc. Common Stock | 31.57x | 45.83% | 89.73% | — | $87.72 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing precision medicines for rare neuroendocrine and metabolic disorders. The company commercializes IMCIVREE (setmelanotide), an approved MC4R agonist for treating hyperphagia and severe obesity caused by rare genetic deficiencies in the MC4R pathway. Its pipeline includes two next-generation MC4R agonists designed to avoid hyperpigmentation and candidate therapies for congenital hyperinsulinism.